Next Article in Journal / Special Issue
Rapid Collection of Biospecimens by Automated Identification of Patients Eligible for Pharmacoepigenetic Studies
Previous Article in Journal
Cancer Genetic Counselor Information Needs for Risk Communication: A Qualitative Evaluation of Interview Transcripts
Article Menu

Export Article

Open AccessArticle
J. Pers. Med. 2013, 3(3), 251-262; doi:10.3390/jpm3030251

A Method for Biomarker Directed Survival Prediction in Advanced Non-Small-Cell Lung Cancer Patients Treated with Carboplatin-Based Therapy

Karmanos Cancer Institute, Department of Oncology, Wayne State University, Detroit, MI 48201, USA
*
Author to whom correspondence should be addressed.
Received: 30 July 2013 / Revised: 27 August 2013 / Accepted: 30 August 2013 / Published: 12 September 2013
(This article belongs to the Special Issue Feature Paper 2013)
View Full-Text   |   Download PDF [407 KB, uploaded 12 September 2013]   |  

Abstract

Platinum-based chemotherapy is a primary treatment of choice for advanced non-small-cell lung cancer (NSCLC). Analytical methods to specifically evaluate biomarkers predictive of therapeutic efficacy have not been developed. Two randomized phase III trials of carboplatin-based chemotherapy in advanced NSCLC were used for learning and validating the predictive value of ERCC1 in situ protein levels, as measured by accurate quantitative analysis (AQUA). A novel Bayesian method was applied to identify the outcome-based threshold in the learning trial only. Overall survival (OS) was assessed by Kaplan-Meier analysis with log rank testing to determine statistical significance in the validating trial. For patients treated with gemcitabine and carboplatin, the median OS was 9.5 months (95% CI 6.7 to 11.8) for the high ERCC1 group compared to 15.6 months (95% CI 11.6 to 24.8) for the low ERCC1 group in the validation trial (log rank p-value = 0.007). The hazard ratio for low ERCC1 was 0.598 (95% CI, 0.394 to 0.908; p = 0.016) relative to high ERCC1 adjusted for age, sex, and histology. Conclusions: Patients with advanced NSCLC could be stratified into high and low ERCC1 expression groups. Patients with low levels benefited from platinum-based chemotherapy, whereas those with high levels did not.
Keywords: biomarkers; cancer; protein expression; methodology; non-small-cell lung cancer; ERCC1 biomarkers; cancer; protein expression; methodology; non-small-cell lung cancer; ERCC1
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Chen, W.; Bepler, G. A Method for Biomarker Directed Survival Prediction in Advanced Non-Small-Cell Lung Cancer Patients Treated with Carboplatin-Based Therapy. J. Pers. Med. 2013, 3, 251-262.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Pers. Med. EISSN 2075-4426 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top